Paul Wang

Dr. Wang is the Director of the Cardiac Arrhythmia Service and Professor of Medicine and Bioengineering (by courtesy) at Stanford University. He has co-authored textbooks on implantable defibrillators, sudden cardiac death, cardiac resynchronization/ biventricular pacing therapy, and innovations in arrhythmia therapy. Dr. Wang serves as the Editor-in-Chief of one of the field’s most pre-eminent journals, Circulation: Arrhythmia and Electrophysiology. He is a member of the American Heart Association Council Operations Committee, Council on Clinical Cardiology, and the National American Heart Association Science and Clinical Education Lifelong Learning (SCILL) Committee, and past Chair of the American Heart Association Council on Clinical Cardiology ECG and Arrhythmias Committee. For his work in the field, Dr. Wang received the 2017 American Heart Association Council on Clinical Cardiology Distinguished Achievement Award. Dr. Wang serves as the Center Director of the American Heart Association Atrial Fibrillation Strategically Focused Research Network DECIDE Grant to study shared decision making for stroke prevention in patients with atrial fibrillation. Dr. Wang's research studies centers on the development of innovative approaches to the treatment of arrhythmias, including catheter ablation, implantable devices, and diagnostic techniques. Dr. Wang has 20 issued patents. Dr. Wang is co-inventor of a cryoablation method and device that has been the basis of a cryoablation catheter which has been FDA approved (Cryocath, Inc. acquired by Medtronic, Inc.). Catheter cryoablation has been used in over 500,000 patients with atrial fibrillation and supraventricular tachycardias